Maxcyte (MXCT) Receivables (2020 - 2026)

Maxcyte (MXCT) has 7 years of Receivables data on file, last reported at $4.2 million in Q1 2026.

• Receivables for Q1 2026 came in at $4.2 million, down 23.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.2 million (down 23.15% YoY), and the FY2025 annual result was $3.5 million, down 25.18% from the prior year.
• Receivables rose to $4.2 million in Q1 2026 per MXCT's latest filing, from $3.5 million in the prior quarter.
• Over five years, Receivables peaked at $11.2 million in Q4 2022 and troughed at $3.5 million in Q4 2025.
• A 5-year average of $6.6 million and a median of $6.0 million in 2024 frame the typical range for Receivables.
• The sharpest annual moves came in 2023 and 2025: Receivables sank 48.3% in 2023, then soared 82.15% in 2025.
• A 5-year view of Receivables shows it stood at $11.2 million in 2022, then plunged by 48.3% to $5.8 million in 2023, then declined by 18.97% to $4.7 million in 2024, then declined by 25.18% to $3.5 million in 2025, then gained by 21.21% to $4.2 million in 2026.
• Business Quant data shows MXCT's Receivables at $4.2 million in Q1 2026, $3.5 million in Q4 2025, and $8.3 million in Q3 2025.